Human leukocyte antigen variation among Iranian renal transplant recipients

Einollahi, Behzad; Rahimi, Zohreh; Teimoori, Mojtaba

doi:10.5812/nephropathol.8114

Cited by 5 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This allele is very common in southeast Asia, especially in Taiwanese people and Papua New Guinea (near 80%) (14). In Iran, it has a prevalence of 10.2%-11.9% and is one of the most common alleles (15)(16)(17). In our study, in all COVID-19 patients, it has a 36% prevalence, but in severe cases, along with DRB1*11, it was the most common allele present in 53.33% of cases.…”

Section: Discussionmentioning

confidence: 99%

Association Between Human Leukocyte Antigen and COVID-19 Severity

Hajebi¹,

Ajam²,

Saleh³

et al. 2021

ACTA

View full text Add to dashboard Cite

In the last days of 2019, a new coronavirus emerged in Wuhan, China, and less than three months its disease, now called COVID-19, was announced a global pandemic by WHO. COVID-19 usually causes respiratory symptoms and can lead to more severe conditions like ARDS. HLA has a crucial role in regulating the immune system; thus, different HLA allele types can be a protective or risk factor for some diseases, so we aimed to find such associations to determine whether some alleles can predict susceptibility or resistibility to COVID-19 and finally facilitate vaccine development. In this case-control study, 15 admitted COVID-19 cases with severe symptoms and ten individuals with mild COVID-19 symptoms were enrolled in the case and control groups, respectively. They were genotyped for HLA A/B/DR loci using a low-resolution HLA typing test. These alleles were more prevalent in case (severe COVID-19) group: A*24 (53.33% vs 10%), B*50 (20% vs 10%), B*55 (20% vs 10%), DRB1*04 (40% vs 20%) and DRB1*11 (53.33% vs 30%) but the difference was only statically significant in A*24 allele (P=0.027; odd ratio=10.286). A*24 was also more prevalent in all patients than the general population in Iran. A*24 was the only allele more prevalent in severe COVID-19 cases with statistical significance. This allele was reported to be a risk factor for such autoimmune diseases as type 1 diabetes, myasthenia gravis, and systemic lupus erythematosus, which may be related to reported immune system hyperresponsiveness in severe COVID-19 cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Association Between Human Leukocyte Antigen and COVID-19 Severity

Hajebi¹,

Ajam²,

Saleh³

et al. 2021

ACTA

View full text Add to dashboard Cite

show abstract

“…Studies to evaluate HLA polymorphism in Jordan and their effect on kidney transplantation are lacking. However, an Iranian study evaluated 512 kidney transplant recipients and found significant polymorphism in both class 1 and 2 antigens [ 29 ]. In a study done retrospectively at the King Hussein Cancer Centre (KHCC) to evaluate the cause of cancellation of potential kidney transplants, out of 642 possible donations, 143 were cancelled due to donor issue; out of those, 16 (11.2%) potential kidney transplants were cancelled due to ABO incompatibility, 10 (7.1%) other potential donors were positive for cytotoxic antibodies, only 3 (2.1%) had 0% HLA match, and only one (0.7%) potential donor had both cytotoxin antibodies and HLA incompatibility [ 3 ].…”

Section: Promises and Challenges Of Kpe Program In Jordanmentioning

confidence: 99%

“…Studies to evaluate HLA polymorphism in Jordan and their efect on kidney transplantation are lacking. However, an Iranian study evaluated 512 kidney transplant recipients and found signifcant polymorphism in both class 1 and 2 antigens [29]. and only one (0.7%) potential donor had both cytotoxin antibodies and HLA incompatibility [3].…”

Section: Abo and Hla Incompatibilitymentioning

confidence: 99%

Addressing Kidney Transplant Shortage: The Potential of Kidney Paired Exchanges in Jordan

Al-Thnaibat,

Balaw,

Al-Aquily

et al. 2024

Journal of Transplantation

View full text Add to dashboard Cite

Jordan performed the Middle East’s first living-donor kidney transplant in 1972. In 1977, the country became one of the first Arab countries to regulate organ donation and transplantation. Despite these early advances in living donor transplantation, Jordan’s organ donation after brain death program remains inactive, making it challenging to meet organ demand and placing many patients on long transplant waiting lists. As of 2020, only 14.2% of the patients with end-stage kidney disease have access to a living donor. The scarcity of compatible living donors exacerbates Jordan’s organ shortage, leaving patients with extended waits and uncertain transplant prospects. Due to the lack of living donors and the inactive brain death donation program, additional options are needed to meet organ demand. Kidney paired exchange (KPE), emerges as a potential solution to the problem of donor shortage and donor-recipient incompatibility. By allowing living donors to direct their donated organs to different compatible recipients, KPE offers the promise of expanding transplant opportunities for patients without suitable living donors. However, the current Jordanian law restricting living kidney donation to fifth-degree relatives further limits the pool of potential donors, aggravating the organ shortage situation. This article explores the feasibility of implementing KPE in Jordan and proposes an approach to implementing KPE in Jordan, considering ethical and legal aspects to substantially increase kidney transplants.

show abstract

“…While the molecular description for finding is not comprehended, it seems to be isolated from genetic (96). Very different genetic markers such as HLA, POR*28 allele, ABCB1, NFKB1, and many more genotypes (97-99) play a great role in disease and CsA level (98,100), which seem to be of clinical significance. Therapeutic CsA monitoring is still need to adjust CsA dosing after administration of individualized doses (18) also time, other medication and sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients has great impact on CsA blood level that attenuate significance of individual therapy (101)(102)(103).…”

Section: Individualizing Target Range and Adjusting Dose Of Cyclosporinementioning

confidence: 99%

A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients

Einollahi

Teimoori

2017

Nephro-Urol Mon

Self Cite

View full text Add to dashboard Cite

Context: An immunosuppressive drug, Cyclosporine (CsA), has been commonly used in kidney transplants. A safe dosing of CsA often causes nephrotoxity, bone marrow toxicity, and infection. Pharmacokinetic characteristics of CsA and CsA marker relation to the immune suppression have not been completely described in clinical practices yet. Objectives: This review summarizes our achievements on pharmacokinetic and CsA level Marker in kidney transplant patients. Search methods and Selection criteria: A literature review was done using the National Center for Biotechnology Information's Pubmed Medline, Ovid Medline and Embase, and Iranian registries (Iranmedex, SID, MagIran, and IranDoc). Titles and abstracts were then reviewed to select studies based upon the predefined inclusion criteria. Our study defined a population of adult solid organ transplant recipients receiving the cyclosporine that Cyclosporine monitoring was done. Data Collection and Analysis: Two reviewers independently appraised the quality of each trial and extracted the data from the included trials. Results: CsA pharmacokinetics is very different between kidney transplant recipients, in order to CsA profiling, no pharmacodynamic tools has been confirmed yet in clinical practices and the best way to individualize calcineurin inhibitor therapy is still a controversial issue. C0 levels do not exactly predict the CsA level or rejection risk, patient monitored by C2 levels have upper doses of CsA and have a lower frequency of early acute allograft rejection than patients profiled with C0 and although CA is highly heterogeneous closely post-transplant and seems to be unhelpful early after post-transplant it is more favorable after first months after. Conclusions: Establishing a biological CsA marker may be helpful in clinical decisions on the dose. It seemed to be logical that we should re-inspect the possibility of using them as a supplementary tool towards better therapeutic drug monitoring of cyclosporine or it needs to be reevaluated and needs to find a new target for a therapeutic plan in kidney transplant patients.

show abstract

Human leukocyte antigen variation among Iranian renal transplant recipients

Cited by 5 publications

References 16 publications

Association Between Human Leukocyte Antigen and COVID-19 Severity

Association Between Human Leukocyte Antigen and COVID-19 Severity

Addressing Kidney Transplant Shortage: The Potential of Kidney Paired Exchanges in Jordan

A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients

Contact Info

Product

Resources

About